Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Dexmedetomidine-esketamine combination
The First People's Hospital of Lianyungang
Liver Cancer
1 trial -
Dextrometropine and 0.9% sodium chloride solution
The First People's Hospital of Lianyungang
Cataract
1 trial -
Diagnostic Test: conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT
The First People's Hospital of Lianyungang
DLL3-expressing Tumors
1 trial -
Diagnostic Test: standard-of-care imaging (68Ga-PSMA PET/CT), 68Ga-XACP3 PET/CT
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
Diaphragmatic Ultrasound
Hospital Authority, Hong Kong
Diaphragmatic Paralysis
1 trial -
Diclofenac
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
Disitamab Vedotin combined with Zimberelizumab
The First People's Hospital of Lianyungang
Biliary Carcinoma
1 trial -
Dobutamine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Patients With Septic Shock
1 trial -
Docetaxel
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
Docetaxel
The First People's Hospital of Lianyungang
Esophageal Neoplasms
1 trial -
Drug
The First People's Hospital of Lianyungang
Herpes Zoster
1 trial -
Drug treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Prolactinoma
1 trial -
Drugs and Stimulation
The First People's Hospital of Lianyungang
Hearing Loss, Sudden
1 trial -
Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc
The First People's Hospital of Lianyungang
Diabetes
1 trial -
Dynamometric tension assessment
The First People's Hospital of Lianyungang
Incisional Hernia
1 trial -
EPCs plus PTA
The First People's Hospital of Lianyungang
Diabetic Foot
1 trial -
ERA
Peking University Third Hospital
Infertility, Female
1 trial -
ET-01
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Transfusion Dependent Beta-Thalassaemia
1 trial -
EVM18001 Injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
System Lupus Erythematosus(SLE)
1 trial -
Early Nutrition Intervention
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nutrition
1 trial -
Eefooton oral solution
Hospital Authority, Hong Kong
Chronic Kidney Diseases
1 trial -
Efgartigimod + Telitacicept (1-week interval) group
The First People's Hospital of Lianyungang
Myasthenia Gravis
1 trial -
Elmental diet
Hospital Authority, Hong Kong
Gastro-oesophageal Reflux
1 trial -
Entecavir
Hospital Authority, Hong Kong
Hepatocellular Carcinoma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources